Business Context and Reporting Period
Company: The Cigna Group (CI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: The Cigna Group is a global health company operating through two primary platforms: Evernorth Health Services (pharmacy benefit management, specialty pharmacy, and care services) and Cigna Healthcare (medical benefits, including U.S. and International health plans). The company serves approximately 182 million customer and patient relationships across more than 30 countries with a global workforce of approximately 73,500.
Key Financial Metrics
| Metric (in millions, except per share) | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenues | $247,121 | $195,265 | +27% |
| Shareholders' Net Income (GAAP) | $3,434 | $5,164 | -34% |
| Adjusted Income from Operations | $7,741 | $7,448 | +4% |
| Diluted EPS (GAAP) | $12.12 | $17.39 | -30% |
| Diluted EPS (Adjusted) | $27.33 | $25.09 | +9% |
| Operating Cash Flow | $10,363 | $11,813 | -12% |
| Total Debt | $32,000 | $30,930 | +3% |
| Debt-to-Capitalization Ratio | 43.8% | 40.1% | N/A |
Note: Adjusted metrics exclude net investment gains/losses, amortization of acquired intangibles, and special items.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 27% to $247.1 billion, driven primarily by a 35% increase in pharmacy revenues ($185.4 billion) due to higher prescription drug utilization and customer growth in Evernorth Health Services.
- GAAP Net Income Decline: Shareholders' net income decreased 34% to $3.4 billion. This decline was primarily caused by a $2.7 billion impairment loss on the Company's investment in VillageMD and the absence of foreign deferred tax benefits recorded in 2023.
- Adjusted Performance: Adjusted income from operations increased 4% to $7.7 billion, reflecting higher earnings in Evernorth Health Services, partially offset by lower earnings in Cigna Healthcare due to higher medical costs.
- Customer Base: Total medical customers decreased 3% to 19.1 million, primarily due to a decline in Individual and Family Plans (IFP) customers.
- Segment Performance:
- Evernorth Health Services: Adjusted revenues grew 32% to $202.2 billion; pre-tax adjusted income increased 9% to $7.0 billion.
- Cigna Healthcare: Adjusted revenues grew 3% to $52.9 billion; pre-tax adjusted income decreased 6% to $4.2 billion, impacted by higher medical costs and a 190 basis point increase in the Medical Care Ratio (MCR).
Guidance, Outlook, and Risks
Key Transactions and Outlook
- HCSC Divestiture: In January 2024, the Company entered into an agreement to sell its Medicare Advantage, Medicare Part D, and related businesses to Health Care Service Corporation (HCSC) for an initial purchase price of $3.3 billion (expected to increase at closing). The transaction is expected to close in Q1 2025. Proceeds are anticipated to be used primarily for share repurchases.
- Capital Allocation: The Board increased share repurchase authorization by $6.0 billion in December 2024. The Company repurchased approximately 20.9 million shares for $7.0 billion in 2024. Dividends were increased to $1.51 per share for Q1 2025.
- Investment Outlook: Management expects to deploy approximately $1.4 billion in capital expenditures in 2025, primarily for technology.
Material Risks and Contingencies
- Regulatory and Legal: The Company faces ongoing scrutiny regarding pharmacy benefit management practices, including an FTC complaint filed in September 2024 alleging anticompetitive rebate practices. The Company is also subject to a Corporate Integrity Agreement (CIA) with HHS-OIG regarding Medicare Advantage risk adjustment practices.
- Cybersecurity: The Company highlighted risks related to cyberattacks, noting a February 2024 ransomware attack on Change Healthcare (a vendor) caused limited service disruptions.
- Investment Impairments: The $2.7 billion impairment of the VillageMD investment significantly impacted 2024 GAAP results. Management noted that goodwill and intangible assets ($73.8 billion) remain subject to impairment risk if future cash flow projections are not met.
- Medical Cost Trends: Rising medical costs and utilization trends continue to pressure margins in the Cigna Healthcare segment, particularly in stop-loss and Medicare businesses.
Investor Verification Checklist
- HCSC Transaction Closing: Verify the final purchase price and closing date of the Medicare Advantage divestiture to HCSC in Q1 2025.
- VillageMD Impairment Impact: Confirm the full extent of the $2.7 billion impairment and assess if further investment write-downs are anticipated.
- Medical Cost Trends: Monitor the Medical Care Ratio (MCR) in the Cigna Healthcare segment, which rose to 83.2% in 2024, to evaluate pricing adequacy for future years.
- Regulatory Outcomes: Track the resolution of the FTC complaint regarding PBM rebate practices and the status of the HHS-OIG Corporate Integrity Agreement.
- Share Repurchase Execution: Monitor the utilization of the $9.4 billion remaining share repurchase authority as of February 2025.